Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
about
Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry DiseaseEfficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative groupGender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment.The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience.Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.Clinical utility gene card for: Fabry disease - update 2016.Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRYFabry disease in a Japanese population-molecular and biochemical characteristicsGlucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
P2860
Q28553021-417044E7-6B23-44A0-9D16-828CC1D2616BQ33776219-EECF460D-FB4E-4239-819D-91E8D240F3A9Q33835524-B3958F99-78A9-4F13-AF9A-3A540C9095BFQ37534497-D38DB7C7-C0D2-4EAD-AF96-0FFA7459B858Q39427220-3007F6E9-6AA5-4C4A-B116-2E8754432E36Q42654919-76EC7A51-2EDA-49E4-8C9F-CB26987F1256Q47118738-A0B7D847-B622-4F49-9745-F219CC93E823Q51842157-F12856A4-32AE-4710-BF09-DC21F8E5BFD5Q55478484-9E04CCF7-1EDE-4C8A-8396-0B1C0B85E14EQ57174028-BDD8CDBE-5D63-4B1A-B329-BB3D85EEFF55Q58546994-7E594FFF-5B84-40F8-881D-E5925148D47CQ58794894-9B7F2D82-D3F9-45AF-94A0-BA5522213C1F
P2860
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@ast
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@en
type
label
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@ast
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@en
prefLabel
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@ast
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@en
P2093
P2860
P1476
Long-term effectiveness of aga ...... Fabry Outcome Survey analysis
@en
P2093
Anna Wijatyk
Atul Mehta
Christoph Kampmann
Fabry Outcome Survey Study Group
Michael Beck
Michael West
Roberto Giugliani
Sylvain Larroque
Uma Ramaswami
P2860
P356
10.1016/J.YMGMR.2015.02.002
P577
2015-03-05T00:00:00Z